Polynucleotides targeting nr4a3 and uses thereof
AssigneeLyell Immunopharma, Inc.
InventorsViola LAM, Rachel Christina LYNN
Life of this patent
Estimating the term…
Abstract
The present disclosure provides polynucleotides that are capable of reducing the level of a NR4A3 gene and/or NR4A3 protein in a cell (e.g., immune cell). In some aspects, the polynucleotides comprises a gRNA that specifically targets a region within the NR4A3 gene. The present disclosure also provides the use of such polynucleotides to treat various diseases or disorders.
Claims29
A method of reducing the level of a NR4A3 gene and/or NR4A3 protein in an immune cell, comprising modifying the immune cell with a gene editing tool, which comprises a guide RNA (gRNA), wherein the gRNA is capable of specifically binding to a sequence within the NR4A3 gene and comprises, consists essentially of, or consists of the sequence set forth in any one of SEQ ID NO:
- 94, SEQ ID NO:
- 52, SEQ ID NO:
- 96, SEQ ID NO:
- 53, SEQ ID NO:
- 54, SEQ ID NO:
- 86, SEQ ID NO:
- 83, SEQ ID NO:
- 55, SEQ ID NO:
- 82, SEQ ID NO:
- 56, SEQ ID NO:
- 76, SEQ ID NO:
- 57, SEQ ID NO:
- 75, SEQ ID NO:
- 58, SEQ ID NO:
- 71, SEQ ID NO:
- 61, SEQ ID NO:
- 70, SEQ ID NO:
- 65, SEQ ID NO:
- 68, and SEQ ID NO:
- 67, and wherein after the modifying, the level of the NR4A3 gene and/or NR4A3 protein in the immune cell is reduced as compared to a reference immune cell.
-3. (canceled)
A method of improving one or more properties of an immune cell, comprising contacting the immune cell with a gene editing tool, which comprises a guide RNA (gRNA), wherein the gRNA is capable of specifically binding to a sequence within the NR4A3 gene and comprises, consists essentially of, or consists of the sequence set forth in any one of SEQ ID NO:
- 94, SEQ ID NO:
- 52, SEQ ID NO:
- 96, SEQ ID NO:
- 53, SEQ ID NO:
- 54, SEQ ID NO:
- 86, SEQ ID NO:
- 83, SEQ ID NO:
- 55, SEQ ID NO:
- 82, SEQ ID NO:
- 56, SEQ ID NO:
- 76, SEQ ID NO:
- 57, SEQ ID NO:
- 75, SEQ ID NO:
- 58, SEQ ID NO:
- 71, SEQ ID NO:
- 61, SEQ ID NO:
- 70, SEQ ID NO:
- 65, SEQ ID NO:
- 68, and SEQ ID NO:
- 67, and wherein after the contacting, the one or more properties of the immune cell is improved, as compared to a reference immune cell.
-13. (canceled)
-31. (canceled)
-45. (canceled)
-49. (canceled)
-53. (canceled)
-78. (canceled)
A guide RNA (gRNA) comprising a CRISPR RNA (crRNA) and a trans-activating crRNA (tracrRNA), wherein the crRNA comprises, consists of, or consists essentially of, the sequence set forth in any one of SEQ ID NO:
- 94, SEQ ID NO:
- 52, SEQ ID NO:
- 96, SEQ ID NO:
- 53, SEQ ID NO:
- 54, SEQ ID NO:
- 86, SEQ ID NO:
- 83, SEQ ID NO:
- 55, SEQ ID NO:
- 82, SEQ ID NO:
- 56, SEQ ID NO:
- 76, SEQ ID NO:
- 57, SEQ ID NO:
- 75, SEQ ID NO:
- 58, SEQ ID NO:
- 71, SEQ ID NO:
- 61, SEQ ID NO:
- 70, SEQ ID NO:
- 65, SEQ ID NO:
- 68, and SEQ ID NO:
- 67.
-99. (canceled)
-107. (canceled)
Dependencies are inferred from the claim text.